ImmunityBio Inc. (NASDAQ:IBRX) shares are up on Friday morning as the company completed its manufacturing engineering programs for its NK cell therapy platform.
• ImmunityBio shares are powering higher. Why is IBRX stock surging?
Establishes Safe, Reproducible, Scalable Manufacturing Pathway
ImmunityBio completed its NK2022 (Cancer and Healthy Volunteers) and NK2023 (Healthy Volunteers) programs, which evaluated the safety and reproducibility of its autologous memory cytokine-enhanced natural killer (M-ceNK) cell therapy.
Sixty-four subjects participated, with no serious adverse events reported, and the company highlighted its ability to generate up to five billion NK cells from a single apheresis collection.
Additionally, the company is advancing its phase 1 trial (QUILT-3.076), combining M-ceNK cells with ANKTIVA, which has demonstrated promising antitumor activity across multiple cancer types.
Management Commentary
“These data demonstrate that potent NK cell therapy can be manufactured at scale and administered safely, potentially offering a reliable autologous source of potent NK cells,” said Patrick Soon-Shiong, founder, executive chairman and global chief scientific and medical officer of ImmunityBio.
“The ability to generate up to five billion highly pure NK cells from a single apheresis collection, yielding up to eight to 10 therapeutic doses within 12 days, opens the possibility of creating the ‘World Bank of Natural Killer Cells,’ with NK cells able to be universally donated to any patient without HLA matching,” Soon-Shiong added.
ImmunityBio FDA Resubmission
The FDA, on Monday, acknowledged receipt of ImmunityBio’s sBLA for ANKTIVA in treating BCG-unresponsive non-muscle invasive bladder cancer (NMIBC).
The resubmission follows ongoing discussions with the FDA that began in January 2026.
The agency requested additional data to support its review, leading to the submission of updated efficacy data in March.
ImmunityBio Analyst Consensus & Recent Actions:
The stock carries a Buy Rating with an average price target of $12.57. Recent analyst moves include:
- BTIG: Buy (Target $13 on March 12)
- D. Boral Capital: Buy (Maintains Target to $23 on March 9)
- Piper Sandler: Overweight (Raises Target to $12 on March 4)
ImmunityBio Top ETF Exposure
- Virtus LifeSci Biotech Products ETF (NYSE:BBP): 4.03% Weight
IBRX Stock Price Activity: ImmunityBio shares were up 10.60% at $8.65 Friday at publication, according to Benzinga Pro data.
Image via Shutterstock
Recent Comments